Market News AIOpen the app

JAMA Network Open shared results showing that Novocure's TTFields therapy helped pancreatic cancer patients live longer.

TrialRead the original at fidelity.com
Good for NVCR

Novocure's Phase 3 trial showed a statistically significant median survival improvement when TTFields was added to chemotherapy. The report is a secondary analysis and gives no size for the gain, but the survival result favors the company's treatment.

NVCR · Novocure

AI read · Good for NVCR

The AI's read

The survival result makes the treatment combination more promising for patients with this cancer. The report gives no size for the gain. Its comments about pain describe a care priority, not a reported improvement in pain.

Get alerts for NVCR

Follow Novocure (NVCR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NVCR
Free on the App Store and Google Play, or on the web.